About this deal
i/ii Data obtained from In Vitro testing on dietary fats and sugars Medical Device for supplementary treatment and prevention of excess weight and obesity. Certified Medical Device with safety and efficacy assessed under Medical Device Directive 93/42/EEC Clinical Study References: Glucomannan : double blind placebo controlled clinical study on 20 obese subjects (IMC>30) during 8 weeks, Walsh DE et al. Int. Journal of obesity, 1984; 8(4): 289-93; Chitosan: single blind placebo controlled clinical study on 92 overweight and obese subjects (25 Substituting two main daily meals of an energy-restricted diet with meal replacements contributes to weight loss. Substituting one of the main daily meals of an energy-restricted diet with a meal replacement contributes to the maintenance of weight after weight loss. Glanbia Performance Nutrition (UK Sales Division) Ltd One Victoria Square, Birmingham, England, B1 1BD